Claims for Patent: 5,861,148

Summary for Patent: 5,861,148

Title:	Ophthalmic compositions and process of using
Abstract:	An ophthalmic composition and process for treating blepharitis employing the composition of 0.5-10% of available nonionic surfactant in water to emulsify and remove lipids from the corneal surface.
Inventor(s):	Smith; Stewart Gregory (Yorklyn, DE)
Assignee:
Application Number:	08/766,231
Patent Claims:	1. An aqueous composition to effect a significant improvement for a significant period of time in the treatment of blepharitis consisting essentially of greater than zero to about 1% of at least one tonicity-adjusting agent, greater than zero to about 0.1% of a preservative agent, greater than zero about 0.3% of at least one buffering agent, said ingredients being present in an amount of from 0.07% to 1.4% by weight, said per cent being based upon weight per volume and an amount of a nonionic surfactant comprising a block copolymer of 20-80% ethylene oxide and 80-20% propylene oxide having a molecular weight of about 2000-13000, a viscosity of about 400-3500 centipoises, a surface tension of about 40-50 dynes/centimeter and an HLB value of at least 12 in sterile water sufficient to provide 0.5-10% by weight of available nonionic surfactant. 2. A process to effect a significant improvement for a significant period of time in the treatment of blepharitis comprising (1) contacting the surface of the cornea having lipids on its surface with an aqueous composition consisting essentially of: greater than zero to about 1% of at least one viscosity-adjusting agent, greater than zero to about 0.1% of a preservative agent, greater than zero about 0.3% of at least one buffering agent, said ingredients being present in an amount of from 0.07 to 1.4% by weight, said per cent being based upon weight per volume an amount of a nonionic surfactant comprising a block copolymer of 20-80% ethylene oxide and 80-20% propylene oxide having a molecular weight of about 2000-13000, a viscosity of about 400-3500 centipoises, a surface tension of about 40-50 dynes/centimeter and all HLB value of at least 12 in sterile water sufficient to provide 0.5-10% by weight of available nonionic surfactant to dissolve said lipids on said surface of said cornea; (2) removing said composition containing dissolved lipids; and (3) permitting the mucin and aqueous layers of the natural tear to contact the complete surface of the cornea. 3. A process as in claim 2 wherein said viscosity-adjusting agent is hydroxy propyl methyl chloride. 4. A process as in claim 2 wherein said tonicity-adjusting agent is selected from the group consisting of sodium chloride, potassium chloride and dextrose. 5. A process as in claim 2 wherein said preservative agent is benzalkonium chloride. 6. A process as in claim 2 wherein said buffering agent is selected from the group consisting of monobasic sodium phosphate and anhydrous dibasic sodium phosphate. 7. A process as in claim 2 wherein the amount of said nonionic surfactant is sufficient to provide about 1-5% of available nonionic surfactant.

Details for Patent 5,861,148

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2015-01-23